Edition:
United States

Acceleron Pharma Inc (XLRN.O)

XLRN.O on Consolidated Issue listed on NASDAQ Global Market

29.70USD
9 Dec 2016
Change (% chg)

$-1.78 (-5.65%)
Prev Close
$31.48
Open
$31.74
Day's High
$32.05
Day's Low
$29.39
Volume
703,065
Avg. Vol
325,956
52-wk High
$50.86
52-wk Low
$22.67

XLRN.O

Chart for XLRN.O

About

Acceleron Pharma Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutic candidates that are based on mechanisms, which the human body uses to regulate the growth and repair of its cells and tissues. Its therapeutic candidates... (more)

Overall

Beta: --
Market Cap(Mil.): $1,121.07
Shares Outstanding(Mil.): 37.75
Dividend: --
Yield (%): --

Financials

  XLRN.O Industry Sector
P/E (TTM): -- 41.98 30.40
EPS (TTM): -1.79 -- --
ROI: -33.04 -0.36 15.24
ROE: -35.87 -0.94 16.58

BRIEF-Acceleron Pharma reports Q3 financial and operational results

* Acceleron Pharma reports third quarter 2016 financial and operational results Source text for Eikon: Further company coverage:

Nov 03 2016

U.S. RESEARCH ROUNDUP-Alkermes, Chesapeake Energy Corp, Latam Airlines

Oct 21 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alkermes, Benchmark Electronics and Copa Holdings on Friday. HIGHLIGHTS * Chesapeake Energy Corp : Nomura raises to neutral from reduce * Latam Airlines : Santander raises to buy from hold * Proofpoint Inc : Piper Jaffray raises target price to $90 from $85; overweight Following is a sum

Oct 21 2016

BRIEF-Acceleron Pharma Q2 loss per share $0.59

* Acceleron Pharma reports second quarter 2016 financial and operational results

Aug 04 2016

BRIEF-Acceleron Pharma appoints Thomas McCourt to its board

* Acceleron Pharma appoints Thomas McCourt to its board of directors Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jul 25 2016

BRIEF-Acceleron announces ACE-083 phase 1 results

* Announces ACE-083 phase 1 results at 14th International Congress On Neuromuscular Diseases

Jul 08 2016

Earnings vs. Estimates